Biointron Weekly Reports

News

Biointron’s Q2 2024 Antibody Industry Report is out now! Dive into the latest trends, breakthroughs, and insights shaping the antibody industry. Gain exclusive insights into:?

• ?? Two novel antibody drugs approved for the first time in Q2?

• ?? Top 10 antibody drug deals, including M&As, partnerships, and funding rounds of up to $3B?

• ?? A focus on hot antibody startups launching from stealth mode with up to $1B in funding?

• ?? Trends in generative AI for antibody discovery and companies to watch?

• ?? Updates on therapies with antibody-peptide conjugates and weight-loss medications?

• ?? A list of antibody drugs in late-stage clinical trials to keep an eye out for in Q3?

Download the full report for free here.

Our latest webinar offering is this month! Mark your calendars now for “Accelerating Antibody Drug Discovery with Fully Human Antibody Mouse HUGO-Ab and High-Throughput Single B Cell Screening”.?

?? Date: July 25, 2024?

?? Time: 11AM EST?

With The Antibody Society and featuring Shun Zhou , Ph.D, the R&D Director at Cyagen , this webinar will explore the revolutionary potential of the genome-edited mouse HUGO-Ab, where endogenous VH and VL genes are replaced by fully human VH and VL genes in situ, enabling the generation of fully human antibody molecules. When combined with microfluidic technology-enhanced single B cell screening, this approach allows for the high-throughput and efficient discovery of antibody drug molecules.??

Register now?

This Week’s News?

• FDA approves Kisunla (donanemab-azbt), a humanized IgG1 monoclonal antibody, for adults with early symptomatic Alzheimer's disease?(AD)!?

• Exploiting the Fc base of IgG antibodies to create functional nanoparticle conjugates?

• Unsupervised evolution of protein and antibody complexes with a structure-informed language model?

?

Trends – An Update on Alzheimer’s Antibody Drugs?

The approval of 礼来 ’s Kisunla (donanemab-azbt), a humanized IgG1 monoclonal antibody, is just one of the major advancements for the treatment of Alzheimer's disease (AD)! This drug is now available in the US for adults with early symptomatic AD, including those with mild cognitive impairment (MCI) and mild dementia stage of AD with amyloid pathology. Kisunla is the first and only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed, which can result in lower treatment costs and fewer infusions.?

As the second treatment approved by the FDA that has been demonstrated to slow a decline in memory and thinking abilities, donanemab targets an epitope at the N-terminal of pyroglutamate Aβ (which is found only in the brain amyloid plaques associated with AD). It works by inducing microglial-mediated clearance of existing Aβ plaques with the intent of slowing the progressive decline in cognitive function associated with AD.?

Other antibody drugs for AD that are currently in development or clinical trials include:?

• Aliada Therapeutics ’ subcutaneous antibody, ALIA-1758, targets anti-pyroglutamate amyloid beta (3pE-Aβ), similar to the epitope targeted by donanemab. It uses a transferrin receptor to transport cargo to cells and force degradation and elimination of the plaques.??

• 罗氏公司 's?bispecific antibody, trontinemab, is?delivered by its Brainshuttle module, which also uses the transferrin receptor. It showed “best-in-class” potential based on its ability to quickly clear clumps of amyloid protein from the brains of patients in a small clinical trial.?

• 卫材 and Biogen have initiated a rolling Biologics License Application (BLA) for a weekly, subcutaneous version of Leqembi (lecanemab), the first monoclonal antibody medication approved by the FDA for treatment of AD last year.?

Meanwhile, in the research space, scientists from The National Institutes of Health developed an innovative nasal spray treatment that has shown promising results in clearing harmful tau protein build-up and improving cognitive functions in aged mice models with neurodegenerative diseases.?They developed a toxic tau conformation–specific monoclonal antibody-2 (TTCM2), which selectively recognized pathological tau aggregates in brain tissues from patients with AD, dementia with Lewy bodies (DLB), and progressive supranuclear palsy (PSP). This study could be valuable in designing effective tau immunotherapies for AD and other tauopathies.?

?

Upcoming Events?

Tomorrow, Biointron will be attending BIOPLUS-INTERPHEX KOREA 2024. Held at COEX in Seoul from July 10-12, join our expert team in a bio-pharmaceutical exhibition with keynote sessions, over 30 conferences, partnering, open innovation, and networking opportunities to expand overseas by building global business networks. Connect with us here.?

Later this month, the Biointron team will also be attending BIO Asia–Taiwan 2024 on July 24-28 at TaiNEX in Taipei. Meet us at Booth #L530!

Promotions – New Package ???

RushMab? - Gene is your go-to solution for quick plasmid production, designed specifically for antibody-related research. We offer a 4-day turnaround, delivering high-quality, transfection-grade expression plasmids for IgG, Fab, VHH, and ScFv sequences. We provide quantities of 100 μg (sufficient for 100 ml culture) with scalability up to grams. Using the reliable pcDNA3.4 backbone, we also accommodate custom vectors. Each plasmid undergoes Sanger sequencing verification and endotoxin control, ensuring precision and safety.??

?? 100ug transfection grade expression plasmids?

?? 4-day turnaround?

?? Sequencing verification, endotoxin control

?

New Products & Reports?

• Q2 2024 Antibody Industry Report is out now!?

• Small-Scale Packages-RushMab??

• Umabs DB: A database for antibody therapeutics?

• CHOK1-FUT8 Afucosylated Antibody Expression Platform?

Learn more about Biointron at www.biointron.com, or contact us at [email protected] and +1 (732) 790-8340.